Search

Your search keyword '"POMALIDOMIDE"' showing total 3,260 results

Search Constraints

Start Over You searched for: Descriptor "POMALIDOMIDE" Remove constraint Descriptor: "POMALIDOMIDE"
3,260 results on '"POMALIDOMIDE"'

Search Results

201. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

206. Pomalidomide Improves Motor Behavioral Deficits and Protects Cerebral Cortex and Striatum Against Neurodegeneration Through a Reduction of Oxidative/Nitrosative Damages and Neuroinflammation After Traumatic Brain Injury.

207. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.

208. Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study.

209. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

210. Johnson & Johnson announces positive results from phase 3 CARTITUDE-4 study of Carvykti to treat relapsed or lenalidomide-refractory multiple myeloma

212. GSK announces Blenrep combo reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory MM

220. Hereditary hemorrhagic telangiectasia

221. Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

223. Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules

224. Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

225. Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

226. Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

227. Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

228. EU Contract Notice: Centre Hospitalier Universitaire de Liege Issues contract notice|solicitation for 'CONCLUSION OF A FRAMEWORK AGREEMENT WITH A SINGLE AWARDEE FOR THE SUPPLY OF POMALIDOMIDE (1 MG, 2 MG, 3 MG, 4 MG) FOR A PERIOD OF TWO YEARS, RENEWABLE TWICE FOR A PERIOD OF ONE YEAR'

229. Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis

230. Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

231. Florida Cancer Specialists & Research Institute Building Knowledge And Improving Outcomes for Patients With Blood Cancers

232. Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience

238. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival

239. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease

240. Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomidebased regimens (KMM170).

241. Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.

242. Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma.

243. Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience.

249. Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Catalog

Books, media, physical & digital resources